Login / Signup

Management of the positive sentinel lymph node in the post-MSLT-II era.

Brooke C BredbeckEman MubarakDaniela G ZubietaRachael TesoreroAdam R HolmesLesly A DossettKyle K VanKoeveringAlison B DurhamTasha M Hughes
Published in: Journal of surgical oncology (2020)
Rates of CLND in SLNB+ melanoma decreased dramatically, albeit not uniformly, following MSLT-II. Factors that increased the likelihood of immediate CLND were primary tumor located in the head and neck and high sentinel node tumor burden. These groups were underrepresented in MSLT-II, suggesting that clinicians are wary of implementing active surveillance recommendations for patients perceived as higher risk.
Keyphrases